BioCryst Pharmaceuticals Inc (BCRX)vsHaleon plc (HLN)
BCRX
BioCryst Pharmaceuticals Inc
$8.12
-2.05%
HEALTHCARE · Cap: $2.25B
HLN
Haleon plc
$9.19
-0.33%
HEALTHCARE · Cap: $44.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 1086% more annual revenue ($11.15B vs $940.61M). HLN leads profitability with a 14.5% profit margin vs -40.9%. HLN appears more attractively valued with a PEG of 2.48. BCRX earns a higher WallStSmart Score of 55/100 (C-).
BCRX
Buy55
out of 100
Grade: C-
HLN
Buy51
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 45.1%
Revenue surging 33.6% year-over-year
Earnings expanding 1400.0% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Areas to Watch
Expensive relative to growth rate
ROE of -1925.0% — below average capital efficiency
Distress zone — elevated risk
Currently unprofitable
Expensive relative to growth rate
2.2% revenue growth
Grey zone — moderate risk
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : BCRX
The strongest argument for BCRX centers on Operating Margin, Revenue Growth, EPS Growth. Revenue growth of 33.6% demonstrates continued momentum.
Bull Case : HLN
The strongest argument for HLN centers on Price/Book, Operating Margin.
Bear Case : BCRX
The primary concerns for BCRX are PEG Ratio, Return on Equity, Altman Z-Score.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth, Altman Z-Score.
Key Dynamics to Monitor
BCRX profiles as a hypergrowth stock while HLN is a value play — different risk/reward profiles.
BCRX carries more volatility with a beta of 0.56 — expect wider price swings.
BCRX is growing revenue faster at 33.6% — sustainability is the question.
HLN generates stronger free cash flow (792M), providing more financial flexibility.
Bottom Line
BCRX scores higher overall (55/100 vs 51/100) and 33.6% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioCryst Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small molecule drugs. The company is headquartered in Durham, North Carolina.
Visit Website →Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?